Capricor rises after US FDA extends review of muscle disorder therapy
BUZZ-Capricor rises after US FDA extends review of muscle disorder therapy ** Shares of Capricor Therapeutics CAPR.O rise 8.8% to $8.85
** Co says the U.S. Food and Drug Administration has extended the review of its experimental cell therapy for Duchenne muscular dystrophy by three months to November 22
** The extension will allow more time to review new clinical trial data submitted by the company for the drug deramiocel
** Deramiocel aims to treat Duchenne, a rare and progressive genetic disease that causes muscle wasting and mostly affects boys
** Co says it submitted an amendment to the application that includes 24-month open-label extension data from its late-stage study and additional analyses supporting a narrower proposed indication focused on preserving upper limb function in patients with Duchenne muscular dystrophy
** In July, an FDA advisory panel voted nine-to-three against the effectiveness data of the drug
** Including session's moves, stock down 73% YTD
(Reporting by Siddhi Mahatole)